KLK3 and neoplasm: Although post chemotherapeutic factors, including PSA decline, tumor response, and pain response, are often used to evaluate patient’s prognosis [15, 16], it might be more beneficial for CRPC patients to predict the response and outcome before the initiation of chemotherapy.